ORION PHARMA - Dry Powder Inhaler Experts

Product info | 19/12/2022

Prescribing information for the Easyhaler^® range is available here.

Easyhaler^® is a dry powder inhaler containing different active pharmaceutical ingredients for treatment of asthma and chronic obstructive pulmonary disease. Easyhaler^® has been used for over 4 million patient years. It has been researched, developed and manufactured by Orion Pharma. Did you know that Easyhaler is the first inhaler range to be certified as carbon neutral.¹

Orion Pharma is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients.

Established in 1917, Orion has become a clear market leader in Finland, and the company’s products have been commercialised in over a hundred countries. Orion’s headquarters, manufacturing plants and most of its R&D operations are located in Finland. The company has 26 affiliates across Europe and Orion products are sold through partners in a number of other countries in the Middle-East and Asia.

Orion continuously develops new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are central nervous system disorders, oncology and respiratory for which Orion develops inhaled Easyhaler^® pulmonary drugs.

Orion has a high-level expertise in the areas of dry powder formulation and drug delivery to the lung. Easyhaler^® is one of Orion’s key products and focus areas in R&D.

If you want to learn more about Orion Pharma, Easyhaler^® production and sustainable life cycle management of the product family, watch the video below.

References

Carbon Neutral Certificate for Easyhaler^® product range. Orion Pharma. Data on file.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Orion Pharma (UK) Ltd on
01635 520300.

August 2025 / RESP-330bbd(3)

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being for more than 100 years. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. Respiratory diseases are one of Orion’s core therapy areas. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki.^®

You can download the Orion Sustainability Report 2022 here

As a forward-looking pharmaceutical company, Orion continues to invest in research and development of treatment options for people with asthma and COPD. The focus is on safety and quality in each step of the product life cycle while taking care of the environment. Sustainability is entwined in the whole process from R&D through manufacturing. It is also required of Orion’s providers. Orion is committed to keeping the best possible control of the environmental impacts of their own factories by reducing energy consumption and the impact of their waste waters, among others, and is making good progress in that regard. Orion works to ensure that suppliers have procedures in place to control and reduce their own environmental impacts as well. All aspects of sustainability - social, economic and environmental - are carefully considered in the whole product life cycle, including patient use and the disposal of old inhalers.